These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38181672)

  • 21. The application of HER2 and CD47 CAR-macrophage in ovarian cancer.
    Chen Y; Zhu X; Liu H; Wang C; Chen Y; Wang H; Fang Y; Wu X; Xu Y; Li C; Lv X; Huang J; Han X; Li R; Hong W; Yu Z; Wei W; Tu J
    J Transl Med; 2023 Sep; 21(1):654. PubMed ID: 37740183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunostimulant Hydrogel-Guided Tumor Microenvironment Reprogramming to Efficiently Potentiate Macrophage-Mediated Cellular Phagocytosis for Systemic Cancer Immunotherapy.
    Liang JL; Jin XK; Luo GF; Zhang SM; Huang QX; Lin YT; Deng XC; Wang JW; Chen WH; Zhang XZ
    ACS Nano; 2023 Sep; 17(17):17217-17232. PubMed ID: 37584451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
    Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
    Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
    Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
    [No Abstract]   [Full Text] [Related]  

  • 25. Cancer immunotherapy targeting the CD47/SIRPα axis.
    Weiskopf K
    Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
    Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
    MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Restoration of miR-340 controls pancreatic cancer cell
    Xi Q; Zhang J; Yang G; Zhang L; Chen Y; Wang C; Zhang Z; Guo X; Zhao J; Xue Z; Li Y; Zhang Q; Da Y; Liu L; Yao Z; Zhang R
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the CD47/thrombospondin-1 signaling axis regulates immune cell bioenergetics in the tumor microenvironment to potentiate antitumor immune response.
    Stirling ER; Terabe M; Wilson AS; Kooshki M; Yamaleyeva LM; Alexander-Miller MA; Zhang W; Miller LD; Triozzi PL; Soto-Pantoja DR
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36418073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
    Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
    Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD47/SIRPα pathway mediates cancer immune escape and immunotherapy.
    Jia X; Yan B; Tian X; Liu Q; Jin J; Shi J; Hou Y
    Int J Biol Sci; 2021; 17(13):3281-3287. PubMed ID: 34512146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD47-signal regulatory protein α signaling system and its application to cancer immunotherapy.
    Murata Y; Saito Y; Kotani T; Matozaki T
    Cancer Sci; 2018 Aug; 109(8):2349-2357. PubMed ID: 29873856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Novel PD-L1-Containing MSLN Targeting Vaccine for Lung Cancer Immunotherapy.
    Zeng W; Pan J; Fang Z; Jia J; Zhang R; He M; Zhong H; He J; Yang X; Shi Y; Zhong B; Zeng J; Fu B; Huang M; Liu H
    Front Immunol; 2022; 13():925217. PubMed ID: 35795680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a.
    Peluso MO; Adam A; Armet CM; Zhang L; O'Connor RW; Lee BH; Lake AC; Normant E; Chappel SC; Hill JA; Palombella VJ; Holland PM; Paterson AM
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32345627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Localized CD47 blockade enhances immunotherapy for murine melanoma.
    Ingram JR; Blomberg OS; Sockolosky JT; Ali L; Schmidt FI; Pishesha N; Espinosa C; Dougan SK; Garcia KC; Ploegh HL; Dougan M
    Proc Natl Acad Sci U S A; 2017 Sep; 114(38):10184-10189. PubMed ID: 28874561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In situ self-assembled peptide enables effective cancer immunotherapy by blockage of CD47.
    Lv MY; Xiao WY; Zhang YP; Jin LL; Li ZH; Lei Z; Cheng DB; Jin SD
    Colloids Surf B Biointerfaces; 2022 Sep; 217():112655. PubMed ID: 35785715
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis.
    Liu R; Wei H; Gao P; Yu H; Wang K; Fu Z; Ju B; Zhao M; Dong S; Li Z; He Y; Huang Y; Yao Z
    Oncotarget; 2017 Jun; 8(24):39021-39032. PubMed ID: 28380460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Durable antitumor responses to CD47 blockade require adaptive immune stimulation.
    Sockolosky JT; Dougan M; Ingram JR; Ho CC; Kauke MJ; Almo SC; Ploegh HL; Garcia KC
    Proc Natl Acad Sci U S A; 2016 May; 113(19):E2646-54. PubMed ID: 27091975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.
    Voets E; Paradé M; Lutje Hulsik D; Spijkers S; Janssen W; Rens J; Reinieren-Beeren I; van den Tillaart G; van Duijnhoven S; Driessen L; Habraken M; van Zandvoort P; Kreijtz J; Vink P; van Elsas A; van Eenennaam H
    J Immunother Cancer; 2019 Dec; 7(1):340. PubMed ID: 31801627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Understanding the regulation of "Don't Eat-Me" signals by inflammatory signaling pathways in the tumor microenvironment for more effective therapy.
    Karizak AZ; Salmasi Z; Gheibihayat SM; Asadi M; Ghasemi Y; Tajbakhsh A; Savardashtaki A
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):511-529. PubMed ID: 36342520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.